Strong Commercial Execution and Growth Potential Drive Buy Rating for Kiniksa Pharmaceuticals

Analyst Nicholas Lorusso of TD Cowen maintained a Buy rating on Kiniksa Pharmaceuticals, retaining the price target of $60.00.

Nicholas Lorusso has given his Buy rating due to a combination of factors that highlight Kiniksa Pharmaceuticals’ strong commercial execution and growth potential. The company is expected to exceed market expectations for Arcalyst sales in Q3:2025, with an anticipated revenue of $170 million, surpassing the consensus estimate of $166 million. This growth is attributed to an expanding prescriber base and increased market penetration, which are expected to drive further acceleration in sales.
Furthermore, the consistent growth over 16 consecutive quarters for Arcalyst, along with the significant increase in repeat prescribers, indicates a robust demand for the product. With only a fraction of the potential prescriber market currently tapped, there is substantial room for further expansion. The increasing comfort among physicians in prescribing Arcalyst and the penetration into the multiple recurrence patient market underscore the potential for continued growth, supporting the Buy rating.

In another report released on October 20, Citi also maintained a Buy rating on the stock with a $50.00 price target.

Based on the recent corporate insider activity of 121 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of KNSA in relation to earlier this year.